Quincy Chu

A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors

Paul C. McDonald, Stephen Chia, Philippe L. Bédard et al. · American Journal of Clinical Oncology · 2020 · 250 citations · Full text

Medicine, Oncology, Pharmacology +16

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

Quincy Chu, Bahram Forouzesh, Samira Syed et al. · Investigational New Drugs · 2007 · 61 citations

Medicine, Oncology, Pharmacology +14

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies

Quincy Chu, Lisa A. Hammond, Garry Schwartz et al. · Clinical Cancer Research · 2004 · 48 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas—NCIC-CTG IND 200

Quincy Chu, Torsten O. Nielsen, Thierry Alcindor et al. · Annals of Oncology · 2015 · 45 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies

Monica Mita, Eric K. Rowinsky, M. Goldston et al. · Journal of Clinical Oncology · 2004 · 41 citations

Medicine, Pharmacokinetics, Pharmacology +16